Johnson & Johnson's Multiple Myeloma Drugs Show Improved Cancer-Free Survival
Johnson & Johnson announced that its FDA-approved drugs Tecvayli and Talvey, used for treating multiple myeloma, demonstrated improved outcomes in reducing the risk of cancer progression or death when combined. The results come from a late-stage trial.
Tickers: $JNJ
Topics: FDA-approved treatments multiple myeloma Talvey Tecvayli